ProKidney Corp. cash flow to debt ratio of -2.98K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

ProKidney Corp.'s free cash flow has increased -13.18% from $-155.86M last year to $-135.31M, signaling increasing performance

ProKidney Corp.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

ProKidney Corp.'s debt has increased relative to shareholder equity from -0.00 last year to 0.01 today, signaling weakened financials

ProKidney Corp. has a net cash position, so leverage is healthy.

ProKidney Corp. earns at least as much interest as it pays. Interest obligations are fully covered.

ProKidney Corp.'s profit margin has increased (-86.83%) in the last year from -80.51K% to -10.60K%, signaling increasing performance

ProKidney Corp.'s short-term assets of $280.68M exceed its short-term liabilities of $30.74M

ProKidney Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

ProKidney Corp.'s return on equity of 12.30%, is lower than 15.00%, indicating bad performance

ProKidney Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ProKidney Corp. had positive net income in only 0 out of 5 years, indicating unstable earnings

ProKidney Corp. has negative free cash flow, indicating the company is burning cash rather than generating it

ProKidney Corp. has negative free cash flow, indicating cash burn

ProKidney Corp.'s yearly earnings has decreased 12.75% since last year from $-61.19M to $-68.99M, signaling decreasing performance

ProKidney Corp.'s yearly revenue has increased 1.07K% since last year from $76.00K to $893.00K, signaling increasing performance

ROIC -68.42% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

ProKidney Corp. has insufficient revenue history to calculate 3-year revenue CAGR.

ProKidney Corp. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

ProKidney Corp. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

ProKidney Corp. has insufficient data to evaluate this check.

ProKidney Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ProKidney Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

ProKidney Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

ProKidney Corp. has insufficient data to evaluate this check.

ProKidney Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ProKidney Corp. has a price-to-book ratio of 1.41x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

ProKidney Corp. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue